Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0KYOBC
ADC Name
TORL-1-23
Synonyms
TORL 1 23; TORL 1-23; TORL-1-23; TORL1-23
   Click to Show/Hide
Organization
TORL Biotherapeutics LLC
Drug Status
Phase 1
Indication
In total 1 Indication(s)
Solid tumor
Phase 1
Clinical Trial
Drug-to-Antibody Ratio
4
Antibody Name
Undisclosed
Antigen Name
Claudin-6 (CLDN6)
  Antigen Info 
Payload Name
Monomethyl auristatin E
  Payload Info 
Therapeutic Target
Microtubule (MT)
  Target Info 
Conjugate Type
Undisclosed
General Information of The Activity Data Related to This ADC
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type NCT Number Clinical Status Clinical Trial Description
Undisclosed  NCT05103683
Phase 1
A phase 1, first in human, dose-escalation study of TORL-1-23 in participants with advanced cancer.
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Related Clinical Trial
NCT Number NCT05103683  Clinical Status Phase 1
Clinical Description A phase 1, first in human, dose-escalation study of TORL-1-23 in participants with advanced cancer.
References
Ref 1 A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer